Pan tumor Nivolumab Rollover Study
Research type
Research Study
Full title
Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
IRAS ID
276888
Contact name
Avinash Gupta
Contact email
Sponsor organisation
Bristol-Myers Squibb International Corporation
Eudract number
2018-004362-34
ISRCTN Number
ISRCTN00000000
Clinicaltrials.gov Identifier
Duration of Study in the UK
5 years, 0 months, 30 days
Research summary
The purpose of this study is to collect the long-term safety and survival information in participants with different tumour types who will be provided nivolumab or have finished treatment and are now in or have completed follow-up on a Bristol-Myers Squibb (BMS) clinical research study (parent study). The Sponsor for this clinical research study is Bristol-Myers Squibb (BMS)
There is not a specific number of patients participating. Enrolment in the study is on a rolling basis and is dependent on the patient’s status in the BMS clinical trial (parent study). Their participation may be either:
• as a participant who is being treated with nivolumab from a previous BMS clinical trial. The study doctor will continue to assess long-term safety and survival information.
• as a participant who is being followed for survival or has completed follow-up from a previous BMS clinical study, having completed, discontinued, or progressed on treatment, and/or on another therapy. The study doctor will continue to assess long-term safety and survival.This study is being conducted at multiple clinical sites in the United Kingdom and Europe.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
20/YH/0147
Date of REC Opinion
17 Jul 2020
REC opinion
Further Information Favourable Opinion